Sandoz eyes lead in European generic semaglutide market as patents unwind

Sandoz is preparing to become the leading European supplier of generic semaglutide tablets as Novo Nordisk’s patents unwind, according to Handelsblatt.

Patent landscape and market opportunity

Semaglutide, the active ingredient in Novo Nordisk’s GLP‑1 weight‑loss drugs, is “gradually losing patent protection,” the Handelsblatt report notes. The erosion of patents creates a market that analysts estimate could be worth several billions of euros for generic manufacturers, although the packet does not provide a precise figure.

Patent expiry is a staged process: individual claims on the molecule and its formulation are set to lapse over the next few years, meaning that generic entrants will face a staggered window of opportunity rather than a single launch date.

Sandoz’s strategy

Swiss generics giant Sandoz, headquartered in Basel, has announced that it intends to produce low‑cost generic copies of semaglutide and to position itself as the market leader in Europe. The company’s chief financial officer, Remco Steenbergen, told Handelsblatt that the firm is “aiming to be the leading provider of generic semaglutide in Europe.”

According to the packet, Sandoz’s plan hinges on leveraging its existing manufacturing capacity and its experience in biosimilar production. The firm employs 5,724 people (Wikidata) and has a long‑standing presence in the European generics market, which should facilitate rapid scale‑up once regulatory clearance is obtained.

Sandoz’s approach is to price the generic tablets below the branded price point, thereby appealing to national health‑service budgets and private insurers that are under pressure to contain drug‑spending.

Competitive context

Novo Nordisk, based in Bagsværd, Denmark, remains the patent holder and the commercial driver of the branded semaglutide products. The company’s chief executive, Lars Fruergaard Jørgensen, is listed in the SEC filing data attached to the packet, but the packet does not contain any comment from Novo Nordisk on the impending generic competition.

Because the packet provides no statements from Novo Nordisk, the article cannot assert how the company plans to defend its market share, whether through new formulations, price adjustments, or litigation. The lack of such information is noted as an uncertainty.

Uncertainties and outlook

Several variables could affect Sandoz’s ambition. First, regulatory approval timelines for generic biologics in the EU can be lengthy, and the packet does not specify when Sandoz expects to file its marketing‑authorisation applications.

Second, the exact timing of each patent expiry is not detailed in the packet, leaving the window for market entry ambiguous.

Third, price dynamics will depend on negotiations with national health‑service agencies, which are not covered in the source material.

Finally, the competitive response from Novo Nordisk or other generics firms could alter market share projections. The packet does not contain any competing claims, so the analysis remains focused on Sandoz’s stated intent.

Analysis

If Sandoz succeeds in launching a generic version soon after the first patent lapses, the European market could see a rapid price decline for semaglutide, mirroring past patterns observed with other GLP‑1 agents. This would likely increase patient access, especially in countries with tighter reimbursement budgets.

From an investor perspective, the move adds a potentially high‑margin product to Sandoz’s pipeline, but the upside is contingent on successful regulatory clearance and the ability to achieve cost‑effective manufacturing at scale. The absence of concrete timeline data in the packet means that any valuation impact must be treated as speculative.

For policymakers, the emergence of a low‑cost generic could ease fiscal pressure on health‑care systems that are currently grappling with the high cost of branded GLP‑1 therapies.

Overall, the evidence in the packet confirms Sandoz’s strategic intent but leaves key timing and competitive‑response questions unanswered.